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ScienceDirectThe interface between viruses and their hosts’ are hot spots for
biological and biotechnological innovation. Bacteria use
restriction endonucleases to destroy invading DNA, and
industry has exploited these enzymes for molecular cut-and-
paste reactions that are central to many recombinant DNA
technologies. Today, another class of nucleases central to
adaptive immune systems that protect bacteria and archaea
from invading viruses and plasmids are blazing a similar path
from basic science to profound biomedical and industrial
applications.
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In retrospect, we probably should have anticipated that
bacteria and archaea would have sophisticated immune
systems. After all, viruses are the most abundant biologi-
cal agents on the planet, causing roughly 1023 infections
every second [1–3]. The selective pressures imposed by
viral predation have resulted in the evolution of numerous
phage defense systems, but it was only recently that
sophisticated adaptive defense systems were identified
in both bacteria and archaea [4–7].
Initial indications that Clustered Regularly Interspaced
Short Palindromic Repeats (CRISPRs) were part of an
adaptive defense system came from a series of bioinfor-
matics observations revealing that the short spacer
sequences embedded in CRISPRs were sometimes iden-
tical to sequences found in phages and plasmids [8–10].www.sciencedirect.com These observations led to the hypothesis that CRISPRs are
central components of an adaptive immune system, and in
2007 Barrangou et al. provided the first demonstration
of adaptive immunity in bacteria by monitoring CRISPR
loci in phage-challenged cultures of Streptococcus thermo-
philus [11]. This paper showed that CRISPRs evolve by
acquiring short fragments of phage-derived DNA and
strains with new spacers are resistant to these phages. It
was immediately clear that this paper would serve as a
foundation for an emerging team of scientists interested in
understanding the mechanisms of adaptive defense sys-
tems in bacteria and archaea, but few of us anticipated the
broader impacts of these discoveries for new applications in
genome engineering.
Building on this initial foundation, a series of mechanistic
studies showed that CRISPR loci are transcribed and
processed into a library of small CRISPR derived RNAs
(crRNAs) that guide dedicated nucleases to complemen-
tary nucleic acid targets [5–7,12,13]. In nature, these
RNA-guided nucleases provide bacteria and archaea with
sequence specific resistance to previously encountered
genetic parasites. However, sequence specific nucleases
have considerable value in biotechnology and one of
these CRISPR-associated nucleases (i.e. Cas9) has re-
cently been co-opted for new applications in biomedical,
bioenergy, and agricultural sciences [14–17].
A goldmine for biotechnology
The molecular interface between a parasite and its host is
a hot spot for innovation. A resistant host has a competi-
tive advantage over a susceptible host, but an obligatory
parasite faces extinction unless it is able to subvert host
defense mechanisms. This conflict results in an acceler-
ated rate of evolution that stimulates genetic innovation
on both sides of this molecular arms race.
Genes at the interface of a genetic conflict have proven to
be a goldmine for enzymes with activities that can be
creatively repurposed for applications in biotechnology.
In the 1970s, basic research on bacteriophages led to the
discovery of DNA restriction endonucleases, which trans-
formed molecular biology by making it possible to cleave
specific DNA sequences [18]. The discovery of these
enzymes paved the way for the emergence of recombi-
nant DNA technologies, and in 1978 Werner Arber,Current Opinion in Virology 2015, 12:85–90
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Prize in Physiology or Medicine ‘for the discovery of restric-
tion enzymes and their application to problems of molecular
genetics’ [19]. Identification and application of type II
restriction enzymes, which are integral to almost every
aspect of DNA manipulation, effectively triggered the
emergence of a global biotech industry.
Like restriction enzymes, CRISPR systems evolved as
components of a prokaryotic defense system. However
the mechanisms of sequence recognition by these
enzymes are fundamentally different. Unlike DNA re-
striction enzymes, which typically rely on protein medi-
ated recognition of 4–8 bp; CRISPR-associated nucleases
are guided by base pairing between an RNA-guide and a
complementary target. The implications of this targeting
mechanism have triggered a sea-change in biology and
now the historical precedent of nucleases in biotechnolo-
gy seems poised to repeat itself.
Why all the fuss?
Reverse genetics is a powerful method used to determine
the biological function of a specific gene. This approach is
used routinely to determine gene function in organisms
with simple genomes, but existing techniques are not
applicable for high-throughput genetic screens in organ-
isms with large genomes and multiple chromosomes.
However, the recently discovered mechanism of DNA
cleavage by the CRISPR RNA-guided nuclease Cas9
[20], has transformed the field of genetics by allowing
efficient and precise genetic manipulation of diverse
eukaryotic genomes, including human cells [14–17]. To
repurpose the Cas9 nuclease for targeted genome editing,
the cas9 gene has been codon optimized for expression in
eukaryotic systems and tagged with a nuclear localization
signal (NLS) [21,22,23]. Cas9 and the guide RNA
have been delivered to eukaryotic cells by transient
transfections with expression vectors [24] or purified
Cas9/sgRNA [25,26], viral transduction using Lenti-
viruses [27,28,29] or Adeno-Associated Virus [30–33],
and cytoplasmic or nuclear injections [34–37] (Figure 1). In
each case, RNA-guided targeting of Cas9 to a complemen-
tary DNA target results in a double-stranded DNA break
(DSB) at the target site.These lesions are typically repaired
by non-homologous end joining (NHEJ), which is an error-
prone process that is often accompanied by insertion or
deletion of nucleotides (indels) at the targeted site, result-
ing in a genetic knock-out of the targeted gene due to a
frameshift mutation. Alternatively, DSBs are repaired by
homology directed repair (HDR). In most systems, HDR is
an inefficient process that requires a DNA donor with
sequence homology to regions of the genome that flank
the DSB [38]. Using Cas9 in combination with a DNA
donor provides a method to target cleavage and repair of
naturally occurring genetic defects, add foreign DNA
encoding genes with new functions to specific locations,
or precisely excise defined fragments of DNA [14–16,39].Current Opinion in Virology 2015, 12:85–90 Cas9 is not the first programmable nuclease developed
for engineering eukaryotic genomes [40]. Some of the
earliest methods for introducing targeted genome mod-
ifications relied on meganucleases (e.g. HO and I-SceI),
which are endonucleases that have long recognition
sequences (12–40 bp) [41]. The enhanced specificity
of these nucleases, as compared to the 4–8 bp recog-
nized by most restriction enzymes, presents an oppor-
tunity to target specific locations in large eukaryotic
genomes. However, these enzymes rely on protein-
mediated recognition of the target DNA, and repro-
gramming these proteins to target new DNA sequences
has been challenging due to the integrated nature of the
DNA binding and nuclease domains of these proteins.
To address this issue, non-natural chimeric nucleases
composed of distinct DNA binding and nuclease
domains have been engineered. The most celebrated
examples of these are Zinc finger nucleases (ZFNs)
and transcription activator-like effector nucleases
(TALENs).
Zinc fingers (ZFs) are sequence specific DNA binding
domains found in eukaryotic transcription factors and
transcription activator-like effectors (TALEs) are modu-
lar DNA binding proteins made by bacterial pathogens
that infect plants. The mechanism of DNA recognition by
these proteins is well understood and the modular nature
of these interactions has been exploited for reprogram-
ming. While the success of these proteins for targeted
genome engineering cannot be overstated, they both rely
on protein-mediated recognition of the DNA, which
means that every new target requires the engineering
of new proteins. In contrast to these techniques, Cas9 is
an RNA-guided nuclease that relies on complementary
base pairing and protein mediated recognition of an
adjacent short sequence motif, commonly referred to as
the PAM (protospacer adjacent motif) [42]. PAMs are
typically 2–5 bp in length, which means that PAMs occur
at high frequency and are rarely a limitation when de-
signing RNA guides to specific target sequences. How-
ever, Cas9 proteins from different organisms often
recognize different PAM sequences, so in rare instances
where a target sequence does not contain a PAM recog-
nized by one Cas9 (i.e. Cas9 from Streptococcus pyogenes
recognizes a 50-NGG PAM), then another Cas9 with a
distinct PAM recognition sequence may be used (i.e.
Cas9 from Neisseria meningitides recognizes a 50-
NNNNGATT PAM) [43]. The diversity of Cas9 proteins
and the simplicity of RNA-guided programing abrogates
the need for sophisticated protein engineering, and
affords rapid generation of designer nucleases. In fact,
guide RNAs that target Cas9 to as many as 20 000 differ-
ent genes and 1800 microRNAs in the human genome
have been generated in a single experiment [28,29,44].
These whole-genome knockout techniques are trans-
forming functional genomics and redefining the possibil-
ities of reverse genetics.www.sciencedirect.com
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Cas9 delivery and repair of the targeted DNA. Cas9 and a single-guide RNA (sgRNA) have been delivered to eukaryotic cells by several methods:
transient transfections (expression vectors or purified Cas9/sgRNA complex), cytoplasmic or nuclear injections (expression vectors, mRNA or
purified Cas9/sgRNA) and by transduction (Lentiviruses or Adeno-Associated Virus). Cas9 identifies its target by protein mediated PAM (yellow)
recognition and base pairing between the sgRNA and the DNA target. Target recognition activates the nuclease sites (red triangles), resulting in
double stranded breaks (DSBs) 3–4 nucleotides downstream from the PAM. DSBs can be repaired by non-homologous end joining (NHEJ) or
homology directed repair (HDR). NHEJ results in insertion or deletions (indels), which often results in a frameshift mutation. HDR relies on
homologous recombination with a donor DNA molecule. This donor DNA can be used to specifically insert desired sequences.The emerging market
CRISPR applications span almost every industry that
involves biological systems (Table 1). Danisco (DuPont)
was an initial pioneer of commercial use of CRISPR
technology to enhance viral immunity in bacteria used
to make yogurts and cheese, but other markets have been
rapidly emerging. Applications in agriculture have lower
regulatory hurdles than biomedical application and some
of these markets are anticipated to produce earlier returns
on investments. Dow Agrosciences has co-developed
intellectual property (IP) with Sangamo Biosciences for
developing genetically modified crops using Cas9, and
Cellectis Plant Sciences is leveraging its relationship with
parent Cellectis SA to move the technology into crops.
Similarly, Recombinetics Inc. is using TALENs, ZFNswww.sciencedirect.com and Cas9 to enhance productivity in the livestock indus-
try [45]. While the USDA has yet to decide on how it will
treat genomes edited using Cas9, it has already ruled that
ZFNs and TALENs do not fall under their governance
[46]. This saves an average 5.5 years and $35 million in
related regulatory costs for bringing a product to market
[47]. Similar treatment of CRISPR-based genome editing
may stimulate economic activity around the development
of new agricultural and industrial products.
In addition to Cas9-based applications in the agricultural
industry, market segments for Cas9 endonucleases within
the human health sectors are experiencing frenetic
growth. These markets include: gene-therapy, cell-ther-
apy, and immuno-therapy, fast and efficient developmentCurrent Opinion in Virology 2015, 12:85–90
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Table 1. Industry interests in Cas9-based technologies
Industry sector Product/application Company Intellectual property
Food Yogurt, cheese Danisco (DuPont) 7 919 277; 8 361 725; 13/722 539;11/990 885
Crops Dow Agrosciences PCT/US2013/039979 co-owned with
Sangamo Biosciences
Livestock Recombinetics PCT/US2014/0201857
Crops Cellectis Plant Sciences Boston Children’s Hosp., Institut Pasteur
License
Laboratory Research tools System Biosciences US 14/216 655
Expression systems Sigma-Aldrich PCT/US2013/073307
Research tools GE Healthcare Broad License
Animal models Sage Caribou, Broad License
Research tools ThermoFisher Cellectis Sublicense
Animal models Taconic Broad License
Sublicensing Ag, Industrial, Bio Caribou PCT/US2013/053287
Medical Pharmaceuticals Novartis Caribou License
In vitro applications only Cellectis Boston Children’s Hosp., Institut Pasteur License
Target validation AstraZeneca Open Innovation Model
Therapeutics Crispr Therapeutics PCT/US2013/032589
Monogenic diseases Sangamo Biosciences PCT/US2013/032381; PCT/US2013/039979;
PCT/US2013/028348
Therapeutics Intellia Caribou License
Therapeutics Editas Broad, Duke, MGH Licensesof transgenic research animals, drug discovery, as well as
target validation and screening. It is difficult to accurately
estimate the value of the nascent market for CRISPR
RNA-guided nucleases in the biomed sector, but docu-
ments from the initial public offering (IPO) of Horizon
Discovery Group, plc., which has in-licensed Cas9 IP,
indicate a market size of $46 billion [48] and recent
private equity financings of Cas9-based genome engi-
neering companies include: Caribou Biosciences (undis-
closed venture estimated at $2.9 million from Novartis),
CRISPR Therapeutics ($25 million), Recombinetics, Inc.
($5 million), Intellia Therapeutics ($15 million), and
Editas Medicine ($43 million). In total, companies with
an interest in using Cas9 for applications related to gene
therapy have raised over $600 million in venture capital
and public markets since the beginning of 2013. The pace
of this activity is remarkable given that the first granted
patent for the use of CRISPR technology in eukaryotic
cells was issued April 15, 2014.
Commercial interest in Cas9 IP has not escaped the
interest of big pharmaceuticals. Novartis has partnered
with a tier I private equity firm, Atlas Ventures to commit
$15 million to kick start Intellia Therapeutics, and Pfizer
partner Cellectis SA will be using Cas9-based technolo-
gies to make T-cells with chimeric antigen receptors. In
January of this year, AstraZeneca announced four partner-
ships with academia around the use of Cas9 nucleases to
validate new drug targets.
In addition to the agricultural and biomedical sectors, the
research tools market is also embracing CRISPR-based
technology. Sigma-Aldrich has in-licensed technology inCurrent Opinion in Virology 2015, 12:85–90 order to make, use, and distribute tools for the generation
of modified plant and animal models, custom cell line
creation and for pooled genetic screening. Perhaps the
financial activity in each of these market sectors is height-
ened by over-exuberance common to the early market
development. However, given the scope of current appli-
cations across multiple industries, we see no limits to
research or financial commitments in this space.
Acknowledgements
We are grateful to Jennifer A. Doudna for valuable feedback on this
manuscript. Research in the Wiedenheft lab is supported by the National
Institutes of Health (P20GM103500 and R01GM108888), the National
Science Foundation EPSCoR (EPS-110134), the M.J. Murdock Charitable
Trust, and the Montana State University Agricultural Experimental Station.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Rodriguez-Valera F, Martin-Cuadrado AB, Rodriguez-Brito B,
Pasic L, Thingstad TF, Rohwer F, Mira A: Explaining microbial
population genomics through phage predation. Nat Rev
Microbiol 2009, 7:828-836.
2. Suttle CA: Marine viruses—major players in the global
ecosystem. Nat Rev Microbiol 2007, 5:801-812.
3. Weinbauer MG: Ecology of prokaryotic viruses. FEMS Microbiol
Rev 2004, 28:127-181.
4. Labrie SJ, Samson JE, Moineau S: Bacteriophage resistance
mechanisms. Nat Rev Microbiol 2010, 8:317-327.
5. Sorek R, Lawrence CM, Wiedenheft B: CRISPR-mediated
adaptive immune systems in bacteria and archaea. Annu Rev
Biochem 2013, 82:237-266.www.sciencedirect.com
CRISPR RNA-guided nucleases propel a biotech boom van Erp et al. 896. van der Oost J, Westra ER, Jackson RN, Wiedenheft B:
Unravelling the structural and mechanistic basis of CRISPR-
Cas systems. Nat Rev Microbiol 2014, 12:479-492.
7. Barrangou R, Marraffini LA: CRISPR-Cas systems: prokaryotes
upgrade to adaptive immunity. Mol Cell 2014, 54:234-244.
8. Bolotin A, Ouinquis B, Sorokin A, Ehrlich SD: Clustered regularly
interspaced short palindrome repeats (CRISPRs) have
spacers of extrachromosomal origin. Microbiology 2005,
151:2551-2561.
9. Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Soria E:
Intervening sequences of regularly spaced prokaryotic
repeats derive from foreign genetic elements. J Mol Evol 2005,
60:174-182.
10. Pourcel C, Salvignol G, Vergnaud G: CRISPR elements in
Yersinia pestis acquire new repeats by preferential uptake of
bacteriophage DNA, and provide additional tools for
evolutionary studies. Microbiology 2005, 151:653-663.
11.

Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P,
Moineau S, Romero DA, Horvath P: CRISPR provides acquired
resistance against viruses in prokaryotes. Science 2007,
315:1709-1712.
This paper provides the first direct evidence for adaptive immunity in
bacteria.
12. Hochstrasser ML, Doudna JA: Cutting it close: CRISPR-
associated endoribonuclease structure and function. Trends
Biochem Sci 2015, 40:58-66.
13. Reeks J, Naismith JH, White MF: CRISPR interference: a
structural perspective. Biochem J 2013, 453:155-166.
14. Wilkinson R, Wiedenheft B: A CRISPR method for genome
engineering. F1000Prime Rep 2014, 6:3.
15. Hsu PD, Lander ES, Zhang F: Development and applications of
CRISPR-Cas9 for genome engineering. Cell 2014, 157:1262-
1278.
16. Doudna JA, Charpentier E: Genome editing. The new frontier of
genome engineering with CRISPR-Cas9. Science 2014,
346:1258096.
17. Carroll D: Genome engineering with targetable nucleases.
Annu Rev Biochem 2014, 83:409-439.
18. Roberts RJ: How restriction enzymes became the workhorses
of molecular biology. Proc Natl Acad Sci USA 2005, 102:5905-
5908.
19. Nobel Media (Ed): The Nobel Prize in Physiology or Medicine.
Nobel Media; 1978:2015.
20.

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA,
Charpentier E: A programmable dual-RNA-guided dna
endonuclease in adaptive bacterial immunity. Science 2012,
337:816-821.
This paper provides mechanistic insights that explain how Cas9 can be
used as a programmable nuclease for genome engineering.
21.

Cong L, Ran FA, Cox D, Lin SL, Barretto R, Habib N, Hsu PD,
Wu XB, Jiang WY, Marraffini LA et al.: Multiplex Genome
Engineering Using CRISPR/Cas Systems. Science 2013,
339:819-823.
This is one of the first demonstations that Cas9 can be used for precise
multiplexed genome engineering in mouse and human cells.
22.

Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J: RNA-
programmed genome editing in human cells. Elife 2013,
2:e00471.
This is one of the first demonstations that Cas9 can be used for precise
genome engineering in human cells.
23.

Mali P, Yang LH, Esvelt KM, Aach J, Guell M, DiCarlo JE,
Norville JE, Church GM: RNA-Guided Human Genome
Engineering via Cas9. Science 2013, 339:823-826.
This is one of the first demonstations that Cas9 can be used for precise
genome engineering in human cells, including induced pluripotent stem
cells.
24. https://http://www.addgene.org/CRISPR/.www.sciencedirect.com 25. Kim S, Kim D, Cho SW, Kim J, Kim JS: Highly efficient RNA-
guided genome editing in human cells via delivery of purified
Cas9 ribonucleoproteins. Genome Res 2014, 24:1012-1019.
26. Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH,
Maeder ML, Joung JK, Chen ZY, Liu DR: Cationic lipid-
mediated delivery of proteins enables efficient protein-
based genome editing in vitro and in vivo. Nat Biotechnol
2015, 33:73-80.
27. Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA: Multiplex
CRISPR/Cas9-based genome engineering from a single
lentiviral vector. Nucleic Acids Res 2014, 42:e147.
28.

Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA,
Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG et al.:
Genome-scale CRISPR-Cas9 knockout screening in human
cells. Science 2014, 343:84-87.
This paper demonstates how lentiviral delivery of sgRNAs can be used to
generate human genome knockout libraries for genome-scale screening.
29.

Wang T, Wei JJ, Sabatini DM, Lander ES: Genetic screens in
human cells using the CRISPR-Cas9 system. Science 2014,
343:80-84.
This paper demonstates how lentiviral delivery systems can be used to
generate human genome knockout libraries.
30. Cheng R, Peng J, Yan Y, Cao P, Wang J, Qiu C, Tang L, Liu D,
Tang L, Jin J et al.: Efficient gene editing in adult mouse livers
via adenoviral delivery of CRISPR/Cas9. FEBS Lett 2014,
588:3954-3958.
31. Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN,
Cowan CA, Rader DJ, Musunuru K: Permanent alteration of
PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res
2014, 115:488-492.
32. Maggio I, Holkers M, Liu J, Janssen JM, Chen X, Goncalves MA:
Adenoviral vector delivery of RNA-guided CRISPR/Cas9
nuclease complexes induces targeted mutagenesis in a
diverse array of human cells. Sci Rep 2014, 4:5105.
33. Holkers M, Maggio I, Henriques SF, Janssen JM, Cathomen T,
Goncalves MA: Adenoviral vector DNA for accurate genome
editing with engineered nucleases. Nat Methods 2014, 11:1051-
1057.
34. Horii T, Arai Y, Yamazaki M, Morita S, Kimura M, Itoh M, Abe Y,
Hatada I: Validation of microinjection methods for generating
knockout mice by CRISPR/Cas-mediated genome
engineering. Sci Rep 2014, 4:4513.
35. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R,
Olson EN: Prevention of muscular dystrophy in mice by
CRISPR/Cas9-mediated editing of germline DNA. Science
2014, 345:1184-1188.
36. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, Kang Y, Zhao X,
Si W, Li W et al.: Generation of gene-modified cynomolgus
monkey via Cas9/RNA-mediated gene targeting in one-cell
embryos. Cell 2014, 156:836-843.
37. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F,
Jaenisch R: One-step generation of mice carrying mutations in
multiple genes by CRISPR/Cas-mediated genome
engineering. Cell 2013, 153:910-918.
38. Heyer WD, Ehmsen KT, Liu J: Regulation of homologous
recombination in eukaryotes. Annu Rev Genet 2010, 44:113-139.
39. Terns RM, Terns MP: CRISPR-based technologies:
prokaryotic defense weapons repurposed. Trends Genet
2014, 30:111-118.
40. Carroll D: Genome editing by targeted chromosomal
mutagenesis. Methods Mol Biol 2014, 1239:1-13.
41. Chevalier BS, Stoddard BL: Homing endonucleases: structural
and functional insight into the catalysts of intron/intein
mobility. Nucleic Acids Res 2001, 29:3757-3774.
42. Anders C, Niewoehner O, Duerst A, Jinek M: Structural basis of
PAM-dependent target DNA recognition by the Cas9
endonuclease. Nature 2014, 513:569-573.
43. Hou Z, Zhang Y, Propson NE, Howden SE, Chu L-F,
Sontheimer EJ, Thomson JA: Efficient genome engineering inCurrent Opinion in Virology 2015, 12:85–90
90 Virus structure and expressionhuman pluripotent stem cells using Cas9 from Neisseria
meningitidis. Proc Natl Acad Sci USA 2013.
44. Sanjana NE, Shalem O, Zhang F: Improved vectors and
genome-wide libraries for CRISPR screening. Nat Methods 2014,
11:783-784.
45. Tan W, Carlson DF, Lancto CA, Garbe JR, Webster DA,
Hackett PB, Fahrenkrug SC: Efficient nonmeiotic allele
introgression in livestock using custom endonucleases. Proc
Natl Acad Sci 2013, 110:16526-16531.Current Opinion in Virology 2015, 12:85–90 46. Glorikian H: Gene Editing Will Change Everything—Just Not All at
One Time. 2015:. [ONLINE] Available at: http://www.genengnews.
com/insight-and-intelligence/gene-editing-will-change-
everything-just-not-all-at-one-time/77900351/. [Accessed 18 April
2015].
47. Voytas DF, Gao C: Precision genome engineering and
agriculture: opportunities and regulatory challenges. PLoS
Biol 2014, 12:e1001877.
48. Horizon Discovery Group, Admission Document; 2015.www.sciencedirect.com
